ClinicalTrials.gg
RecruitingNCT05935384Updated Sep 11, 2026

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

An observational study in Non-small Cell Lung Cancer, Colorectal Cancer and Breast Cancer, sponsored by Guardant Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Guardant Health, Inc. · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
470
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
60th of 246
470 · median 100
Started
2023
with 163 others
Observational
246 of 3,374
49 open now
Primary completion
2030-12
later than 830 of 893 live
Registered
2,883rd of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 60th largest by planned enrollment of the 246 observational ones that give a count, is one of 164 that started in 2023, is one of 246 observational ones, reaches primary completion later than 830 of the 893 other live ones, and was the 2,883rd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1 and CT scan measurements.

03

Conditions studied

  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The primary study population will include participants with Non-small cell lung cancer (stage III-IV), Colorectal adenocarcinoma (stage III-IV), and Breast Cancer (stage III-IV), as per inclusion/exclusion criteria. Approximately 470 total patients will be enrolled into the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must satisfy all the following criteria to be enrolled in the study:

  1. Age ≥18 years old
  2. Are treated with systemic therapy and/or oral SOC regimen at the site of enrollment during entirety of study
  3. Patient is either treatment naive and has not yet commenced SOC therapy OR patient has completed first line SOC therapy and will commence second line of SOC therapy
  4. Able to understand, and capable of providing written consent to participate in the study
  5. Are willing to have de-identified clinical data shared with investigators at regular intervals outlined in the study protocol and
  6. Are willing to provide blood samples at enrollment and at subsequent clinical visits
  7. Have a confirmed Index cancer that qualifies for inclusion, defined as:

    • Cohort 1: Unresectable Stage III/IV NSCLC (\~125)
    • Cohort 2: Stage IV Colorectal (\~125)
    • Cohort 3: Unresectable Stage III/IV Breast - HR+ - (\~55)
    • Cohort 4: Unresectable Stage III/IV Breast - HR- HER2+ (\~55)
    • Cohort 5: Unresectable Stage III/IV Breast - HR+ HER2+ (\~55)
    • Cohort 6: Unresectable Stage III/IV Breast - Triple Negative (\~55) Determination of stage for eligibility assessment and enrollment should be based on clinical or pathologic stage.

Exclusion criteria

Exclusion Criteria

Any potential participant who meets and of the following criteria at the time of initial enrollment will be excluded from participating in the study:

  1. History of prior solid or hematological malignancy within five years of enrollment
  2. ≤12 weeks
  3. Unable to collect a baseline blood sample during a SOC venipuncture, and prior to starting SOC regimen
  4. Is participating in a clinical trial or another observational study that is evaluating the performance of another genomic test for detecting/predicting clinical response/progression
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
470 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Unresectable Stage III/IV NSCLC

    Blood samples collected will be banked

    Diagnostic Test: Guardant360

  • Cohort 2: Stage IV Colorectal

    Blood samples collected will be banked

    Diagnostic Test: Guardant360

  • Cohort 3: Unresectable Stage III/IV Breast - HR+ HER2-

    Blood samples collected will be banked

    Diagnostic Test: Guardant360

  • Cohort 4: Unresectable Stage III/IV Breast - HR- HER2+

    Blood samples collected will be banked

    Diagnostic Test: Guardant360

  • Cohort 5: Unresectable Stage III/IV Breast - HR+ HER2+

    Blood samples collected will be banked

    Diagnostic Test: Guardant360

  • Cohort 6: Unresectable Stage III/IV Breast - Triple Negative

    Blood samples collected will be banked

    Diagnostic Test: Guardant360

Interventions

  • Diagnostic testGuardant360

    Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.

06

What researchers measure

Primary outcomes

  1. Sensitivity of ctDNA to Detect Disease Progression

    The Primary Endpoint, sensitivity of ctDNA to detect disease progression, will be evaluated from all eligible subjects within the primary study cohorts (breast cancer, NSCLC, or CRC)

    Time frame: 6 years

Secondary outcomes

  1. RECIST Response

    RECIST v1.1 response: defined as the tumor response to treatment as measured by restaging scans in subjects who have increasing or decreasing ctDNA quantities before the time of scan and correlating this change with the clinical response

    Time frame: 6 years

  2. Progression-Free Survival (PFS)

    PFS: defined as the quantitative changes in ctDNA that correlate or associate with participant's progression free survival on each line of SOC therapy

    Time frame: 6 years

  3. Lead Time

    Lead time: defined as the interval between ctDNA detection or increase and clinical detection of disease progression

    Time frame: 6 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2030, 86 months after the start.

Of 142 industry-sponsored observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's planned 86 months is above that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 7, 2023
StartActual
Oct 25, 2023
Primary completionEst.
Dec 30, 2030
CompletionEst.
Dec 30, 2030
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05935384
Lead sponsor
Guardant Health, Inc.
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Oct 25, 2023
Primary completion
Dec 30, 2030 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Sep 11, 2026

Study contacts

Clinical Trial Operations
Contact
sibyl@guardanthealth.com
8556988887

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion